Mission
Our core technology (HVJ-E) is an immunopromoter that targets RIG-I. It is a platform technology for the development of immunotherapeutic drugs. We are developing advanced drugs by the combination of gene, nucleic acid and cell therapy-drugs with our platform technology. Our drugs are expected to be effective for the treat,ent of incurable diseases such as cancers and drug resistant-infectious diseases.